canakinumab
novartis
['lung', 'canakinumab', 'canopy-a']
targeting il-1b has been proposed yesterday to prevent pollution-induced lung cancer. unfortunately negative trial in an adjuvant trial (canopy-a with canakinumab) presented today #esmo22. might be more protective than curative? 
MD, PhD, Prof of Respiratory Medicine, Thoracic Oncology Specialist @CHUdeToulouse, @IUCTOncopoleICR; Researcher, INSERM @crctoncopole #LCSM ????? ?? ??